Involving Producing Or Treating Antigen Or Hapten Patents (Class 436/543)
-
Patent number: 4559311Abstract: Method for the diagnosis of cancer tumors which comprises determining the concentration of oncofetal urine peptide in the blood serum or the urine of the patient. The oncofetal urine peptide is immunochemically identifiable by means of an antiserum which is produced by the immunization of purified oncofetal urine peptide. The purification method has the following steps:(a) concentrating urine peptides from cancer patients by means of dialyzation and lyophilization;(b) separating the urine peptides having a molecular weight of 4,000 to 10,000 by means of gel filtration to achieve a peptide fraction;(c) concentrating of the peptide fraction through lyophilization;(d) subjecting the peptide fraction to ion exchange chromatography by using SP-Sephadex, gradient elution at pH 4 to 5, ion strength 0.1 to 0.5 mol/l;(e) subjecting the treated peptide fraction to high Pressure Liquid Chromatography using a reverse phase column and eluation in a gradient containing phosphate buffer 10 mmol/l pH 6.Type: GrantFiled: July 21, 1982Date of Patent: December 17, 1985Inventors: Ulf-Hakan Stenman, Marja-Liisa Huhtala
-
Patent number: 4554256Abstract: Early pregnancy can be determined by detection of a protein in serum, which protein is associated with the placental membrane. The protein is characterized by having an approximate molecular weight of 47,000 to 53,000 and an isoelectric point of from about 4.0-4.4.Type: GrantFiled: July 21, 1983Date of Patent: November 19, 1985Assignee: The Idaho Research Foundation, Inc.Inventors: R. Garth Sasser, William C. Hamilton
-
Patent number: 4554101Abstract: An immunoglobulin is provided which consists essentially of a mono-specific, hetero-molecular antibody which is mono-specific to a single antigenic or allergenic determinant. The antibody is specific to the H-epitope of a protein antigen or allergen. The H-epitope is defined by a sequence of at least six amino acids corresponding to the sequence of such amino acids in the protein antigen or allergen where the greatest local average hydrophilicity of the protein antigen or allergen is found.Type: GrantFiled: January 28, 1983Date of Patent: November 19, 1985Assignee: New York Blood Center, Inc.Inventor: Thomas P. Hopp
-
Patent number: 4543325Abstract: The present invention provides a process for the immunological determination of creatinine, wherein creatinine is converted into 1-methylhydantoin, the 1-methylhydantoin formed is incubated in an aqueous medium with antibodies which are directed against a conjugate of a first hydantoin derivative of the general formula: ##STR1## in which R.sup.1, R.sup.2, R.sup.3 and R.sup.4, which can be the same or different, are hydrogen atoms, alkyl radicals containing up to 3 carbon atoms or phenyl radicals, with a first hapten carrier substance suitable for antibody formation, reacted with a conjugate of a second hydantoin derivative of general formula (I) with a second hapten carrier substance, one of the components antibody and conjugate being present in the solid phase or in dissolved form and the other component being present in dissolved form, and the inhibition of the binding reaction between the antibodies and the hydantoin conjugate with the second hapten carrier substance is measured.Type: GrantFiled: December 15, 1982Date of Patent: September 24, 1985Assignee: Boehringer Mannheim GmbHInventors: Winfried Albert, Joachim Ziegenhorn, Joachim Siedel, Hans-Georg Batz, Helmut Lenz, Brigitte Pautz
-
Patent number: 4543340Abstract: A radioimmunoassay for the polypeptide thymic hormone thymosin .beta..sub.4 is described. The assay employs a radiolabelled Tyr-C13-thymosin .beta..sub.4 -analogue as probe and a thymosin .beta..sub.4 antibody.Type: GrantFiled: April 7, 1983Date of Patent: September 24, 1985Assignee: George Washington UniversityInventors: Allan L. Goldstein, Teresa L. K. Low, John McClure, Paul H. Naylor
-
Patent number: 4541953Abstract: Anti-T-lymphocyte globulin is prepared from the serum of immunized animals. Cells of the cell line JM are used for immunization. Anti-T-lymphocyte globulin is prepared by means of hybrid cells, which are obtained by a hybridization of myeloma cells capable of antibody synthesis with B-lymphocytes from animals or human beings. Said lymphocytes have a specificity against an antigen which is introduced. Cells of the cell line JM or their products are used as an antigen.Type: GrantFiled: February 21, 1984Date of Patent: September 17, 1985Inventor: Heidi Thimel-Baumer
-
Patent number: 4542104Abstract: Fluorescent conjugates are employed providing combinations of a fluorescent sensitizer and a fluorescent phycobiliprotein. The conjugates find use in applications where large Stokes shifts, high absorption coefficients and high fluorescence quantum yields are desired. Particularly, combinations of phycobiliproteins are employed where the wavelength of excitation may be 50 nm or more different from the emission wavelength.Type: GrantFiled: April 6, 1983Date of Patent: September 17, 1985Assignee: The Board of Trustees of the Leland Stanford Jr. Univ.Inventors: Lubert Stryer, Alexander N. Glazer
-
Patent number: 4533630Abstract: Mono-specific antibodies for each of toxin A and toxin B of C. difficile are produced and used in an assay for toxin A and toxin B, respectively. Purified toxin A of C. difficile is also produced.Type: GrantFiled: September 13, 1982Date of Patent: August 6, 1985Inventors: Tracy D. Wilkins, David M. Lyerly
-
Patent number: 4529581Abstract: Antigenicity of streptococcal preparations useful for inducing anti-streptococcal immunity in animals can be determined using a combining power technique. Method involves incubating serial dilutions of the antigen preparation with known amounts of anti-streptococcal antiserum, thereby lessening, in serial manner, the combining power of the antiserum. The serial reaction products are then incubated with serial dilutions of streptococcal preparations having known activity and the effects of the serial reaction products on such activity are then determined by in vivo means. Those determinations can be related to a standard for determining potency of the streptococcal preparation. Assay technique is especially useful in determining potency of Streptococcus equi bacterins or bacterin derivatives.Type: GrantFiled: December 30, 1982Date of Patent: July 16, 1985Assignee: Miles Laboratories, Inc.Inventors: Karen K. Brown, Sharon A. Bryant
-
Patent number: 4529582Abstract: Group C streptococcal antibody levels in a serum sample can be determined via passive protection test in susceptible animals. Test is based on property of protective antibody in the serum sample to reduce the virulence of a group C streptococcal challenge and provides a means for detecting whether an animal (e.g. horse) is susceptible to infection by group C streptococcal organism.Type: GrantFiled: December 30, 1982Date of Patent: July 16, 1985Assignee: Miles Laboratories, Inc.Inventors: Karen K. Brown, Sharon A. Bryant
-
Patent number: 4524027Abstract: Membrane-associated proteins, called MP.sub.2, and a process for obtaining them are described. The proteins have the following parameters:(a) an electrophoretic mobility in the range between that of .alpha..sub.2 and that of .beta..sub.1 globulins;(b) an isoelectric point in the pH range 4.4-5.0;(c) a sedimentation coefficient s.sub.20W.sup.c in the range from 7 to above 20 S, the main fractions (IV, III, II and I) sedimenting at about 7, 9, 14 and 20 S respectively;(d) molecular weights in the range from 200,000 to 1,000,000, the main fractions (IV, III, II and I) having molecular weights of about 210,000, 400,000, 750,000 and 1,000,000;(e) an extinction coefficient E.sub.1 cm.sup.1% (280 nm) of 12.5.+-.0.2;(f) a carbohydrate content of 8.0.+-.3.2% (mannose 1.4.+-.0.4%, fucose 0.4.+-.0.2%, galactose 1.2.+-.0.4%, N-acetylglucosamine 2.6.+-.1.8%, and N-acetylneuraminic acid 2.4.+-.1.Type: GrantFiled: September 21, 1984Date of Patent: June 18, 1985Assignee: Behringwerke AktiengesellschaftInventor: Hans Bohn
-
Patent number: 4520113Abstract: This invention relates to the detection of antibodies in sera of AIDS and pre-AIDS patients and describes the biochemical and immunological analysis of antigens associated with the virus HTLV-III Human T-Cell Leukemia Virus. It is shown that antigens associated with the infection of human cells by this virus are specifically recognized by antibodies from AIDS patients. Specifically, HTLV-III isolated from AIDS patients and transmitted by cocultivation with an HT cell line is specifically detected by antibodies from human sera taken from AIDS patients. The method of detection of antibodies preferred is a strip radioimmunoassay (RIA) based on the Western Blot technique or an ELISA (an enzyme-linked immunosorbent assay) or an indirect immunofluorescence assay.Type: GrantFiled: April 23, 1984Date of Patent: May 28, 1985Assignee: The United States of America as represented by the Secretary of the Department of Health and Human ServicesInventors: Robert C. Gallo, Mikulas Popovic, Mangalasseril G. Sarngadharan
-
Patent number: 4514506Abstract: The invention comprises a method for the purification of a human lung tumor-associated antigen (hLTAA) specific to human lung tumors of diverse histological characteristics; serum levels of hLTAA correlate with lung tumor incidence, and appear to usefully discriminate between various stages of the malignancies. The invention further comprises an immunoassay predicated on purified hLTAA for the detection and quantitative determination of hLTAA in biological fluids, particularly blood serum, and diagnostic systems for clinical immunoassay procedures.Type: GrantFiled: January 28, 1983Date of Patent: April 30, 1985Assignee: The Government of the United States as represented by the Secretary of the Department of Health and Human ServicesInventors: James A. Braatz, Kenneth R. McIntire, Gerald L. Princler
-
Patent number: 4511478Abstract: A method is disclosed for the de novo synthesis of polypeptide-containing polymers. This disclosure also includes a description of, and a method for the preparation of, a class of polymerizable compounds used in the synthesis of polypeptide-containing polymers. These polymerizable compounds are chemical conjugates prepared by covalent linkage of polymerizable organic monomers with specific polypeptides. Soluble monomer/polypeptide conjugates can be polymerized in solution with additional nonderivatized organic monomers to form desired polypeptide-containing polymers. The amount and composition of monomer and monomer/polypeptide conjugates can be varied in order to provide control of (a) molecular spacing, steric accessibility, and number of polypeptide molecules that are integrally incorporated into the polymer backbone, and (b) the chemical and physical structure of the polymer itself. This enables the specific tailoring of polypeptide-containing polymers for particular end-use applications.Type: GrantFiled: November 10, 1983Date of Patent: April 16, 1985Assignee: Genetic Systems CorporationInventors: Robert C. Nowinski, Allan S. Hoffman
-
Patent number: 4508830Abstract: There is described an assay for determining the relative concentrations of two antigenic solutes in a sample. The assay involves a first antibody to the first antigenic solute, a second antibody to the second antigenic solute and a ligand molecule having substituents to which the first and second antibodies may bind. The second antibody is immobilized upon a solid phase support and the other components are in solution. The components are mixed with a sample containing the antigenic solutes causing competition between the ligand molecule and each of the antigenic solutes for binding to the first and second antibodies. In the situation where there is a relatively higher concentration of the first antigenic solute to the second antigenic solute in the sample, a significant number of the ligand molecules become attached to the solid phase via the second antibody yet are capable of binding to a labelled antibody having the same specificity as the first antibody.Type: GrantFiled: February 7, 1983Date of Patent: April 2, 1985Inventors: Terence S. Baker, William F. Couslon
-
Patent number: 4508833Abstract: Crude interleukin-2 extract is subjected to group-selective dye-ligand absorption chromatography in one or more stages of purification with a matrix-gel medium consisting of a Blue A ligand or variant thereof or of a Green A ligand in a concentration of approximately 1.5 to 3.0 mg/ml of expanded matrix at a pH of approximately 6.8 to 8.5, a temperature of approximately 4.degree. to 40.degree. C., and a flowthrough rate of approximately 10 to 100 ml/h, employing an eluent. Either PHA-free or extremely pure interleukin-2 is obtained, depending on the overall number of purification stages.Type: GrantFiled: December 14, 1982Date of Patent: April 2, 1985Assignee: Biotest-Serum-Institut GmbHInventors: Hans H. Sonneborn, Udo Schwulera, Hans Schleussner
-
Patent number: 4497899Abstract: The present disclosure relates to a solid phase immunoassay for the detection of Chlamydia trachomatis antigens in a clinical specimen, wherein the Chlamydia trachomatis antigens to be determined are coated or adsorbed on the solid phase.Type: GrantFiled: March 28, 1983Date of Patent: February 5, 1985Assignee: Abbott LaboratoriesInventors: Alan S. Armstrong, John E. Herrmann, Lawrence V. Howard
-
Patent number: 4496658Abstract: In a method for immunochemical assay of human chorionic gonadotropin involving use of an antibody immobilized on a carrier, an antigen and an antibody to which a labeling agent has been attached, when the antibody supported on the carrier and the antibody coupled to a labeling agent are different antibodies which are not overlapping in antigen-determining site and one of said different antibodies is specifically reactive to human chorionic gonadotropin, a high reproducibility of the result of the immunochemical assay is obtained.Type: GrantFiled: October 14, 1981Date of Patent: January 29, 1985Assignee: Takeda Chemical Industries, Ltd.Inventors: Koichi Kondo, Susumu Iwasa, Isamu Yoshida
-
Patent number: 4495296Abstract: A process for detecting the presence of an antigen in a specimen is described, which process comprises:(A) contacting said specimen with a substrate coated with antibodies of said antigen, incubating the contacted substrate and washing the substrate;(B) contacting the washed material of step (A) with a hapten conjugated antibody against said antigen, incubating the so-contacted material and washing the so-incubated material;(C) contacting the washed material of step (B) with a radioactive material labeled or enzyme containing anti-hapten antibody, incubating the so-contacted material and washing the same; and(D) effecting radioimmunoassay if said antibody is radioactive or enzyme labeled immunoassay if said antibody contains an enzyme moiety.Quantitative determination of the antigen in the specimen is effected by comparing the counts of the radioimmunoassay or the concentration of enzyme against a standard as by photocolormetric methods.Type: GrantFiled: May 21, 1979Date of Patent: January 22, 1985Assignee: New York Blood Center, Inc.Inventors: A. Robert Neurath, Nathan Strick
-
Patent number: 4493899Abstract: A method is provided for testing for particular antibodies in the serum of a patient. The antibodies may be those of systemic lupus erythematosus and may constitute IgG and IgM immunoglobulins. The IgG and IgM immunoglobulin may be individually labeled radioactively.An antigen (such as DNA) may be attached to a support such as sepharose. The attachment may be facilitated as by irradiation with ultraviolet light. The DNA may be single stranded or double stranded. When double-stranded DNA is used, single-stranded portions in the double strands may be removed as by a suitable enzyme.The particular antibodies may be attached to the antigen such as the supported DNA. An assay may then be provided to determine the attachment of the particular antibodies to the supported DNA.Type: GrantFiled: October 16, 1981Date of Patent: January 15, 1985Assignee: City of HopeInventors: Lloyd H. Smith, Raymond L. Teplitz
-
Patent number: 4490473Abstract: Sandwich immunoassays are provided wherein an anti-analyte antibody is coupled with a detector labeled antibody, the anti-analyte antibody being substituted with a N,N,N-trimethylammoniumphenyl group and the detector labeled antibody is an antibody specific to the N,N,N-trimethylammoniumphenyl group. The invention includes novel assays, antigens and antibodies.Type: GrantFiled: March 28, 1983Date of Patent: December 25, 1984Assignee: PanAbInventor: Robert F. Brunhouse
-
Patent number: 4489167Abstract: Carcinoembryonic antigen contains immune determinates in common with .alpha.-acid glycoprotein. Carcinoembryonic antigen-containing compositions are purified by adsorption onto antibody to .alpha.-acid glycoprotein. The purified compositions may be employed as standards in carcinoembryonic antigen assays or in the labelled form as tracers. Intact carcinoembryonic antigen is assayed by a modified sandwich-type immunoassay. Other cancer-associated substances may be identified by searching for high molecular weight analogues of normal proteins.Type: GrantFiled: June 2, 1981Date of Patent: December 18, 1984Assignee: Baxter Travenol Laboratories, Inc.Inventors: Yukio Ochi, Takashi Hachiya, Tadayoshi Miyazaki, Yoshihiro Kajita
-
Patent number: 4486534Abstract: A process for the preparation of immunologically active tagged conjugates by covalent linking of an enzyme with an antigen or haptene, which process comprises placing a solution of a mixture of immunologically active and inactive conjugates in contact with an insoluble complex former able to form a non-immunological complex reversibly with the untagged antigen or haptene component of the conjugate, separating the insoluble complex former, and eluting with a desorbent for untagged antigen or haptene.Type: GrantFiled: May 19, 1982Date of Patent: December 4, 1984Assignee: Boehringer Mannheim GmbHInventors: Winfried Albert, Helmut Lenz
-
Patent number: 4480043Abstract: The invention relates to a process for obtaining preparations of toxoplasmas, improved for the diagnosis of toxoplasmosis by direct agglutination, said process comprising, in a first step, the inoculation in mice of a mixture of toxoplasmas and of sarcomatous cells, in a second step the inoculation in other mice of a mixture of sarcomatous cells infected with toxoplasmas coming from the mice of the first step and of non-infected sarcomatous cells, and finally the collection of the ascitic exsudate of these latter mice from 48 to 72 hours after inoculation.Type: GrantFiled: May 12, 1981Date of Patent: October 30, 1984Assignee: BiomerieuxInventor: G/e/ rard Trouyez
-
Patent number: 4478823Abstract: An immunologically active preparation for human or veterinary use comprises an antigenic material in combination with an MHC antigen.Type: GrantFiled: January 10, 1983Date of Patent: October 23, 1984Assignee: National Research Development CorporationInventor: Arnold R. Sanderson
-
Patent number: 4478934Abstract: A method of quantative determination of adenosine by means, of competitive immunoassay based on a competitive antigen-antibody reaction. In the competitive antigen-antibody reaction, an antibody is used which is obtained from an animal which has been immunized by introduction thereto of an antigen which comprises a carrier protein bonded with 2'- and 3'-hydroxyls of the adenosine through dicarboxylic acid residues, and a labelled adenosine and 2',3'-diacyladenosine which has been produced by acylation of adenosine in the sample to be assayed or in a standard solution are caused to undergo competitive reaction for the antibody whereby it has been made possible to determine adenosine quantitatively in high sensitivity and in high accuracy.Type: GrantFiled: July 9, 1982Date of Patent: October 23, 1984Assignee: Yamasa Shoyu Kabushiki KaishaInventors: Tomokazu Sato, Michio Ui
-
Patent number: 4468345Abstract: The protein PP.sub.17, which has (a) an electrophoretic mobility in the range between .beta..sub.1 - and .alpha..sub.2 -globulins, (b) an isoelectric point of 5.25.+-.0.20, (c) a sedimentation coefficient S.sub.20.sup.o, w of 2.7.+-.0.1 S, (d) a molecular weight, determined in polyacrylamide gel containing sodium dodecyl sulfate (SDS), of 38,000.+-.2,000, (e) an extinction coefficient E.sub.1cm.sup.1% (280 nm) of 8.5.+-.0.4 and (f) a carbohydrate content of 2.1.+-.0.9% containing 0.3.+-.0.2% of mannose, 0.4.+-.0.2% of galactose, 0.2.+-.0.1% of xylose, 1.0.+-.0.3% of N-acetyl-glucosamine and 0.2.+-.0.1% of N-acetyl-neuramin acid, is described.A process for concentrating and isolating it and its use are also described.Type: GrantFiled: July 29, 1983Date of Patent: August 28, 1984Assignee: Behringwerke AktiengesellschaftInventors: Hans Bohn, Wilhelm Winckler
-
Patent number: 4468457Abstract: A tryptic peptide is produced by partial tryptic digestion of purified, high molecular size colon-specific antigen-p (CSAp), to produce a lower molecular size antigen carrying the CSAp antigenic determinant. The tryptic peptide is used to produce monospecific anti-CSAp antibodies.Type: GrantFiled: June 1, 1981Date of Patent: August 28, 1984Assignee: David M. GoldenbergInventors: Milton D. Goldenberg, Dan Shochat
-
Patent number: 4468470Abstract: The invention relates to a method for the assay of antibodies to soluble antigens in an aqueous sample, in particular in body fluids, such as blood serum or blood plasma, by contacting said sample with an antigen in vitro, wherein antibodies, if present, are bound by said antigens. The invention furthermore relates to a kit for the assay and detection of antigen-specific antibodies.According to the invention an antigen is used that is modified with a recognizable group, and said modified antigen is soluble in the test sample.The interaction between antigen and antibody takes place in homogeneous solution.Type: GrantFiled: April 30, 1982Date of Patent: August 28, 1984Assignee: Stichting Centraal Laboratorium van de Bloedtransfusiedienst van het Nederlandse Rode KruisInventor: Robertus C. Aalberse
-
Patent number: 4461833Abstract: A chromatographic procedure for the purification of a proteolytic procoagulant enzyme from extracts of human and animal tumors. The extracts are sequentially contacted with a first benzamide affinity chromatographic resin, an agarose filtration gel, a second benzamide affinity chromatographic resin and a phenyl-sepharose hydrophobic chromatographic resin. The resulting enzyme is capable of producing anti-procoagulant antibody which, which used in an immunoassay, is diagnostic for malignancy.Type: GrantFiled: June 23, 1982Date of Patent: July 24, 1984Assignee: University Patents, Inc.Inventor: Stuart G. Gordon
-
Patent number: 4461838Abstract: There are provided a crystalline and single rod products derivable from the Pili of Type 1 and Type 2 Neisseria gonorrhoeae organisms. There are provided methods of growing said organisms to produce the maximum yield of Pili and procedures for purifying said Pili to produce said crystalline material. There are further provided methods of utilizing said Pili to determine the presence, in a system infectable by N. gonorrhoeae organisms, of antibodies to the Pili of said organisms, and methods of serotyping said Pili. There is also provided a mode of utilizing said crystalline material to provide a substantial degree of immunization to infection by N. gonorrhoeae in mammalian systems susceptible to such infection.Type: GrantFiled: September 18, 1980Date of Patent: July 24, 1984Assignee: Bactex, Inc.Inventors: Charles C. Brinton, John C. McMichael
-
Patent number: 4459362Abstract: An immunologic assay for determining the presence of one or more phospholipids in a biological fluid. The method includes adding an ethanolic solution of diacylphosphatidylcholine or alkyltrimethylammonium halide and cholesterol to the biological fluid forming a macromolecular aggregate complex suspension. To the macromolecular aggregate complex solution is then added either an additional quantity of the biological fluid or a buffer reagent. The product of the reaction is then added to antibody molecules to the phospholipid and examined to determine the presence of the phospholipids.The method is particularly useful in determining the presence of phosphatidylglycerol in a sample of amniotic fluid.Type: GrantFiled: September 29, 1982Date of Patent: July 10, 1984Assignee: Hana Biologics, Inc.Inventor: Kenichi K. Yabusaki
-
Patent number: 4456691Abstract: A polychlorinated biphenyl hapten is covalently bonded to a macromolecule carrier through a diazo-containing linking group. In forming the conjugate, a PCB hapten is nitrated, aminated, diazotized and finally coupled with the macromolecule carrier. The antigen may be used to raise antibodies specific to the hapten and binding with the hapten.Type: GrantFiled: February 28, 1983Date of Patent: June 26, 1984Inventor: Suad Stark
-
Patent number: 4455381Abstract: In the immunoassay of a particular protein in a biological fluid, there is frequently interference in the assay by other proteins present in the fluid, e.g. by complement factors or antibodies in human serum. The interference so caused can be avoided by subjecting the fluid to protein-digestion, using for example an enzyme such as pepsin, as a result of which the particular protein of interest, or a fragment thereof, can be assayed without interference by the other proteins. Also, radioallergosorbent tests for particular IgE antibodies can be improved in sensitivity and accuracy, by subjecting the absorbed IgE to enzymic digestion, and then assaying a fragment thereof.Type: GrantFiled: November 6, 1981Date of Patent: June 19, 1984Assignee: International Institute of Cellular and Molecular PathologyInventors: Carl-Gustaf M. Magnusson, Daniel Collet-Cassart, Pierre L. Masson
-
Patent number: 4447547Abstract: The reticulocyte content present in a specimen of red blood cells is quantitatively measured based upon the selective immunoreactivity of the reticulocyte portion of the specimen with a reticulocyte-specific antibody which is immunoreactive with proteinaceous material associated with reticulocytes but not associated with mature red blood cells. Such immunoreactive proteinaceous material may be transferrin, transferrin receptor, transcobalamin II, or transcobalamin II receptor. Various procedures are described for quantitating such selective immunoreactivity, including fluorescent and radioactive detection techniques employing direct or indirect fluorescent or radioactive labeling of the reticulocyte-specific antibody.Type: GrantFiled: March 9, 1982Date of Patent: May 8, 1984Assignee: University Patents, Inc.Inventors: Robert H. Allen, Paul A. Seligman
-
Patent number: 4446122Abstract: A prostate antigen distinct from prostatic acid phosphatase has been detected in normal, benign hypertrophic and malignant prostatic tissues, but not in other human tissues. The prostate antigen was purified to homogeneity from prostatic tissues by ammonium sulfate precipitation, DEAE-BioGel A anion exchange chromatography, molecular sievings on Sephadex G-100 and Sephadex G-75, and preparative polyacrylamide gel electrophoresis. The purified prostate antigen shows a single protein band on analytical polyacrylamide gel electrophoresis and isoelectric focusing. The molecular weight of purified antigen was estimated by Sephadex G-75 gel filtration to be 33,000 and by sodium dodecyl sulfate polyacrylamide gel electrophoresis to be 34,000 with no subunit. The prostate antigen had an isoelectric point of 6.9.Type: GrantFiled: August 28, 1981Date of Patent: May 1, 1984Assignee: Research CorporationInventors: Tsann M. Chu, Ming C. Wang, Lawrence Papsidero
-
Patent number: 4440863Abstract: This disclosure relates to assay of a glycoprotein component of human breast gross cystic disease fluid which has been designated GCDFP-15. This material is a useful marker in monitoring the efficacy of therapy in women with metastatic breast carcinoma and also in determining the maturity of the fetus in pregnant women. The assay for GCDEP-15 can also be used in conjunction with other assays for breast carcinoma such as an assay for carcinoembryonic antigen (CEA) whereby the utilization of both tests is more effective in monitoring for recurrence of disease than using either assay alone.Type: GrantFiled: August 13, 1981Date of Patent: April 3, 1984Assignee: Duke UniversityInventor: Darrow E. Haagensen, Jr.
-
Patent number: 4438208Abstract: Novel oligopeptide used as reagents or in the preparation of reagents in relation to gamma-carboxyglutamic acid-containing protein of bone. Particularly, labeled oligopeptides and antibodies prepared from immunogen conjugates are disclosed for use in immunoassays.Type: GrantFiled: May 27, 1982Date of Patent: March 20, 1984Assignee: The Regents of the University of CaliforniaInventors: Leonard J. Deftos, Bayard D. Catherwood
-
Patent number: 4438207Abstract: An improved immunoassay for detecting cannabinoids is described. This immunoassay is characterized by utilizing, as reagents, antibody, .sup.125 I-radiolabeled antigen, an unlabeled antigen and an anion exchange resin for separation of labeled and unlabeled antigen. The iodinated tetrahydrocannabinol moiety is stabilized by the addition of small quantities of antioxidants such as butylated hydroxy toluene.Type: GrantFiled: April 13, 1981Date of Patent: March 20, 1984Assignee: Hoffmann-La Roche Inc.Inventors: Kenneth E. Fahrenholtz, John E. Heveran
-
Patent number: 4434157Abstract: Disclosed is a vaccine which prevents disease caused by Feline leukemia virus (FeLV) and which comprises a protease enzyme-inhibited, cell-free, ostensibly virusfree, in vitro produced feline leukemia neoantigens including FOCMA which evokes an immune response in cats by the appearance of antibodies thereto and a FeLV virion gp70 neoantigen which evokes an immune response in cats by the appearance of antibodies thereto. A novel method for making the vaccine is disclosed also.Type: GrantFiled: April 7, 1982Date of Patent: February 28, 1984Assignee: The Ohio State University Research FoundationInventor: Richard G. Olsen
-
Patent number: 4434237Abstract: A method for determining the pyrogenicity of a substance, comprising the step of incubating said substance in the presence of a cell mixture for at least 46 hours at 35.degree. to 39.degree. C., wherein the cell mixture comprises human lymphocytes and human monocytes with a cell ratio of lymphocytes to monocytes of at least 2:1 and a composition with respect to the total of all cells present comprising at least 15% monocytes and no more than 10% granulocytes and wherein the cells have a contact ratio of from 0.0 to 0.75.Type: GrantFiled: March 31, 1982Date of Patent: February 28, 1984Inventor: Charles A. Dinarello
-
Patent number: 4432907Abstract: Species-linked diamine triacetic acids of the formula ##STR1## wherein T is an organic species containing at least one amine, hydroxyl, or thio functional group, L is the residue of at least one of those functional groups and R is a two or more atom long covalent bridge, are disclosed. Methods for their preparation, for the preparation of metal chelates from them and for the use of the chelates are also disclosed. In a preferred embodiment, the metal ions employed in the formation of the chelates are rare earth metal ions capable of forming fluorescent chelates which can in turn be employed in fluoroassay techniques.Type: GrantFiled: May 5, 1981Date of Patent: February 21, 1984Assignee: Analytical Radiation CorporationInventors: Irwin Wieder, Robert H. Wollenberg
-
Patent number: 4433051Abstract: There are provided novel labelled derivatives, namely .alpha.-difluoromethylornithine tagged with rhodamine or with biotin. These are of value in analysis and in the cytochemical localization of enzymes.Type: GrantFiled: October 14, 1981Date of Patent: February 21, 1984Assignee: Yeda Research and Development Co., Ltd.Inventors: Gad Gilad, Varda Gilad, Meir Wilchek
-
Patent number: 4427782Abstract: Procedures are presented for isolating the major outer membrane protein of Chlamydia trachomatis. The isolated protein is a species specific antigen which comprises about 60% of the C. trachomatis cell outer membrane structure. The protein has a molecular weight ranging from about 38,000 to 44,000 daltons, with a mean molecular weight of about 39,500 daltons. The protein antigen is purified from C. trachomatis cells by first extracting the cell contents with a mild anionic detergent, preferably sarcosyl, to leave a residue of intact outer cell membranes. These outer cell membranes are then extracted with a strong anionic detergent, preferably sodium dodecyl sulfate, which solubilizes the 39,500 dalton antigen. The antigen is then purified by hydroxlapatite chromatography. The antigen is species specific for Chlamydia trachomatis and may be utilized in assaying Chlamydial infection in mammals.Type: GrantFiled: March 3, 1981Date of Patent: January 24, 1984Inventors: Harlan D. Caldwell, Julius Schacter
-
Patent number: 4427783Abstract: An improved immunoassay for the polypeptide hormone thymosin .alpha..sub.1 is described. The assay employs an improved antibody which is elicited by an immunogen which has been prepared by coupling [Tyr.sup.1 ]-thymosin .alpha..sub.1 to an immunogenic carrier protein using a bifunctional diazonium coupling agent.Type: GrantFiled: December 14, 1981Date of Patent: January 24, 1984Assignee: Hoffmann-La Roche Inc.Inventors: Edward Newman, A. Hirotoshi Nishikawa, Herbert E. Spiegel, Julia Symington
-
Patent number: 4426453Abstract: Novel amides of an iodothyronine compound such as tri-iodothyronine (T3) or thyroxine (T4) with an aminoacetic acid compound such as nitrilotriacetic acid (NTA), ethylenediaminetetraacetic acid (EDTA) or diethylenetriamine pentaacetic acid (DTPA) may be labelled, e.g. radioactively labelled with I-125, to give labelled derivatives useful in assays of a free thyroid hormone in a biological fluid which also contains the thyroid hormone bound to one or more natural binders. The novel compound T4 EDTA is shown to bind much more strongly to antibodies to T4 than to the natural protein binders in the biological fluid.Type: GrantFiled: August 27, 1981Date of Patent: January 17, 1984Assignee: Amersham International LimitedInventors: Gavin M. Cree, Terence A. Wilkins, Reginald Monks, David P. Nowotnik
-
Patent number: 4410634Abstract: The method comprises covalently binding an immuno-reactive to a selected macromolecular carrier and then contacting the resulting hapten-carrier conjugate at a selected concentration in a liquid phase with a selected solid phase until a desired amount of the hapten-carrier conjugate is adsorbed to the surface of the solid phase. Unbound hapten-carrier conjugate is then separated from the solid phase, and the solid phase containing the bound hapten-carrier conjugate is recovered for use in quantitative immunoassays and the like. The solid phase can be, for example, surfaces of a test tube or microtiter well or the like. The method is simple and inexpensive and permits hapten assays of improved sensitivity.Type: GrantFiled: November 12, 1981Date of Patent: October 18, 1983Assignee: Dynasciences CorporationInventors: Harold R. Cooper, Andrew O'Beirne
-
Patent number: 4400376Abstract: An immunological preparation of an antigenic material in combination with a major histocompatibility complex antigen, which is itself in the form of complex with a protein with which it is normally associated in nature or with a modified form of such protein which retains the epitope thereof intact, said antigenic material being attached to the protein of the complex through antibody to that protein, is disclosed as being useful for the production of an immunogenic response in human or veterinary use.Type: GrantFiled: November 17, 1980Date of Patent: August 23, 1983Assignee: National Research Development CorporationInventor: Arnold R. Sanderson
-
Patent number: 4391911Abstract: The invention relates to a process for the industrial production of a product for the diagnosis of carcinoma consisting of an antigen obtained by the infection with Herpes Simplex Virus of cells of guinea-pig kidney, the process comprising three main sections, in the first of which the antigen is produced, in the second section a biochemical purification of the antigen is carried out, while in the third section the product is prepared in preservable condition and confection.Type: GrantFiled: January 25, 1980Date of Patent: July 5, 1983Assignee: Depa S.p.A.Inventor: Giulio Tarro
-
Patent number: 4388412Abstract: An immunologic assay for determining the presence of one or more phospholipids in a biological fluid. The method includes adding an ethanolic solution of diacylphosphatidylcholine or alkyltrimethylammonium halide and cholesterol to the biological fluid forming a macromolecular aggregate complex solution. To this solution is added antibody molecules to the phospholipids in an aqueous buffered medium causing an agglutination reaction. The product of the reaction is then examined to determine the presence of the phospholipids.The method is particularly useful in determining the presence of phosphatidylglycerol in a sample of amniotic fluid. Thus, the assay may be used in evaluating fetal lung maturity.Type: GrantFiled: February 2, 1982Date of Patent: June 14, 1983Assignee: Hana Biologics, Inc.Inventor: Kenichi K. Yabusaki